Methotrexate in psoriatic polyarthritis

P. D. Pigatto, E. Gibelli, R. Ranza, A. Rossetti

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Methotrexate (MTX) is widely accepted as an effective treatment for psoriasis and chronic polyarthrides. We report data from 54 psoriatic polyarthritis patients (354 encounters) treated with MTX. 65% were males, mean age 47.9 years, mean disease duration 9.8 years for arthritis, 14.2 years for psoriasis. The MTX dose was 10-12.5 mg/week. 32 patients are still on MTX after a mean treatment time of 1.6 years. 22 patients discontinued MTX treatment: 11 felt it to be ineffictive, in 6 patients there were side effects, 3 patients obtained remission, while 2 patients underwent surgery. Efficacy was good on the whole: number of swollen and tender joints, global disease activity score, ESR, and CRP all underwent a significant reduction. The intake of symptomatic drugs was reduced in 40%. Psoriasis as assessed with the Psoriasis Activity and Severity Index showed a significant improvement. Our data confirm that MTX is of value in most psoriatic polyarthritis patients (60%). In our experience, this drug, gives the maximum efficacy within 6 months of therapy.

Original languageEnglish
Pages (from-to)114-115
Number of pages2
JournalActa Dermato-Venereologica, Supplement
Issue number186
Publication statusPublished - 1994

Fingerprint

Methotrexate
Arthritis
Psoriasis
Joint Diseases
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Dermatology

Cite this

Pigatto, P. D., Gibelli, E., Ranza, R., & Rossetti, A. (1994). Methotrexate in psoriatic polyarthritis. Acta Dermato-Venereologica, Supplement, (186), 114-115.

Methotrexate in psoriatic polyarthritis. / Pigatto, P. D.; Gibelli, E.; Ranza, R.; Rossetti, A.

In: Acta Dermato-Venereologica, Supplement, No. 186, 1994, p. 114-115.

Research output: Contribution to journalArticle

Pigatto, PD, Gibelli, E, Ranza, R & Rossetti, A 1994, 'Methotrexate in psoriatic polyarthritis', Acta Dermato-Venereologica, Supplement, no. 186, pp. 114-115.
Pigatto, P. D. ; Gibelli, E. ; Ranza, R. ; Rossetti, A. / Methotrexate in psoriatic polyarthritis. In: Acta Dermato-Venereologica, Supplement. 1994 ; No. 186. pp. 114-115.
@article{16eb042688e14b85a93074153f6bc936,
title = "Methotrexate in psoriatic polyarthritis",
abstract = "Methotrexate (MTX) is widely accepted as an effective treatment for psoriasis and chronic polyarthrides. We report data from 54 psoriatic polyarthritis patients (354 encounters) treated with MTX. 65{\%} were males, mean age 47.9 years, mean disease duration 9.8 years for arthritis, 14.2 years for psoriasis. The MTX dose was 10-12.5 mg/week. 32 patients are still on MTX after a mean treatment time of 1.6 years. 22 patients discontinued MTX treatment: 11 felt it to be ineffictive, in 6 patients there were side effects, 3 patients obtained remission, while 2 patients underwent surgery. Efficacy was good on the whole: number of swollen and tender joints, global disease activity score, ESR, and CRP all underwent a significant reduction. The intake of symptomatic drugs was reduced in 40{\%}. Psoriasis as assessed with the Psoriasis Activity and Severity Index showed a significant improvement. Our data confirm that MTX is of value in most psoriatic polyarthritis patients (60{\%}). In our experience, this drug, gives the maximum efficacy within 6 months of therapy.",
author = "Pigatto, {P. D.} and E. Gibelli and R. Ranza and A. Rossetti",
year = "1994",
language = "English",
pages = "114--115",
journal = "Acta Dermato-Venereologica, Supplement",
issn = "0365-8341",
publisher = "Society for the Publication of Acta Dermato-Venereologica",
number = "186",

}

TY - JOUR

T1 - Methotrexate in psoriatic polyarthritis

AU - Pigatto, P. D.

AU - Gibelli, E.

AU - Ranza, R.

AU - Rossetti, A.

PY - 1994

Y1 - 1994

N2 - Methotrexate (MTX) is widely accepted as an effective treatment for psoriasis and chronic polyarthrides. We report data from 54 psoriatic polyarthritis patients (354 encounters) treated with MTX. 65% were males, mean age 47.9 years, mean disease duration 9.8 years for arthritis, 14.2 years for psoriasis. The MTX dose was 10-12.5 mg/week. 32 patients are still on MTX after a mean treatment time of 1.6 years. 22 patients discontinued MTX treatment: 11 felt it to be ineffictive, in 6 patients there were side effects, 3 patients obtained remission, while 2 patients underwent surgery. Efficacy was good on the whole: number of swollen and tender joints, global disease activity score, ESR, and CRP all underwent a significant reduction. The intake of symptomatic drugs was reduced in 40%. Psoriasis as assessed with the Psoriasis Activity and Severity Index showed a significant improvement. Our data confirm that MTX is of value in most psoriatic polyarthritis patients (60%). In our experience, this drug, gives the maximum efficacy within 6 months of therapy.

AB - Methotrexate (MTX) is widely accepted as an effective treatment for psoriasis and chronic polyarthrides. We report data from 54 psoriatic polyarthritis patients (354 encounters) treated with MTX. 65% were males, mean age 47.9 years, mean disease duration 9.8 years for arthritis, 14.2 years for psoriasis. The MTX dose was 10-12.5 mg/week. 32 patients are still on MTX after a mean treatment time of 1.6 years. 22 patients discontinued MTX treatment: 11 felt it to be ineffictive, in 6 patients there were side effects, 3 patients obtained remission, while 2 patients underwent surgery. Efficacy was good on the whole: number of swollen and tender joints, global disease activity score, ESR, and CRP all underwent a significant reduction. The intake of symptomatic drugs was reduced in 40%. Psoriasis as assessed with the Psoriasis Activity and Severity Index showed a significant improvement. Our data confirm that MTX is of value in most psoriatic polyarthritis patients (60%). In our experience, this drug, gives the maximum efficacy within 6 months of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028248966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028248966&partnerID=8YFLogxK

M3 - Article

SP - 114

EP - 115

JO - Acta Dermato-Venereologica, Supplement

JF - Acta Dermato-Venereologica, Supplement

SN - 0365-8341

IS - 186

ER -